ES2483366T3 - Método y composición para el tratamiento de una afección mediada por el receptor de serotonina - Google Patents

Método y composición para el tratamiento de una afección mediada por el receptor de serotonina Download PDF

Info

Publication number
ES2483366T3
ES2483366T3 ES08859016.1T ES08859016T ES2483366T3 ES 2483366 T3 ES2483366 T3 ES 2483366T3 ES 08859016 T ES08859016 T ES 08859016T ES 2483366 T3 ES2483366 T3 ES 2483366T3
Authority
ES
Spain
Prior art keywords
condition
receptor
treatment
composition
ht2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08859016.1T
Other languages
English (en)
Inventor
Mihael H. Polymeropoulos
Paolo Baroldi
Curt D. Wolfgang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanda Pharmaceuticals Inc
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2483366T3 publication Critical patent/ES2483366T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Ácido 4-[3-[4-(6-fluoro-1,2,-bencisoxazol-3-il)-1-piperidinil]propoxi]-3-metoxi-benzoico o sal farmacéuticamente aceptable de este para usar para antagonizar un receptor de 5-HT2A en un animal que padece una afección que es mediada por un receptor de 5-HT2A, en donde la afección se selecciona de un grupo que consiste en: agregación plaquetaria, enfermedad de la arteria coronaria, infarto del miocardio, ataques isquémicos transitorios, angina estable, angina inestable, un evento isquémico secundario, fibrilación auricular, trombosis, restenosis, asma, y una patología asociada con diabetes, y en donde el compuesto está en una forma de dosificación farmacéutica de liberación controlada.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7

Claims (1)

  1. imagen1
    imagen2
ES08859016.1T 2007-12-13 2008-12-13 Método y composición para el tratamiento de una afección mediada por el receptor de serotonina Active ES2483366T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1337707P 2007-12-13 2007-12-13
US13377 2007-12-13
PCT/US2008/086734 WO2009076664A1 (en) 2007-12-13 2008-12-13 Method and composition for treating a serotonin receptor-mediated condition

Publications (1)

Publication Number Publication Date
ES2483366T3 true ES2483366T3 (es) 2014-08-06

Family

ID=40350212

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08859016.1T Active ES2483366T3 (es) 2007-12-13 2008-12-13 Método y composición para el tratamiento de una afección mediada por el receptor de serotonina

Country Status (17)

Country Link
US (3) US8618134B2 (es)
EP (1) EP2222300B1 (es)
JP (2) JP2011506482A (es)
AU (1) AU2008334933B2 (es)
BR (1) BRPI0821131A2 (es)
CA (1) CA2709104C (es)
CY (1) CY1115587T1 (es)
DK (1) DK2222300T3 (es)
ES (1) ES2483366T3 (es)
HR (1) HRP20140701T1 (es)
MX (1) MX2010006521A (es)
NZ (1) NZ585923A (es)
PL (1) PL2222300T3 (es)
PT (1) PT2222300E (es)
SI (1) SI2222300T1 (es)
WO (1) WO2009076664A1 (es)
ZA (1) ZA201004213B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010006521A (es) * 2007-12-13 2010-08-10 Vanda Pharmaceuticals Inc Metodo y composicion para el tratamiento de una condicion mediada por el receptor de serotonina.
US8729100B2 (en) 2007-12-13 2014-05-20 Vanda Pharmaceuticals, Inc. Method and composition for treating an alpha adrenoceptor-mediated condition
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
GB9611356D0 (en) 1996-05-31 1996-08-07 Howard Alan N Improvements in or relating to compositions containing Creatine, and other ergogenic compounds
US5968554A (en) 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation
US6312728B1 (en) 1998-07-07 2001-11-06 Cascade Development, Inc. Sustained release pharmaceutical preparation
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
JP2005504783A (ja) 2001-08-31 2005-02-17 ノバルティス アクチエンゲゼルシャフト イロペリドン代謝産物の光学異性体
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
DE60238780D1 (de) 2001-10-30 2011-02-10 Novartis Ag Depot formulierungen von iloperidone und einem sternförmigen polymer
JP2005512576A (ja) 2001-12-10 2005-05-12 ノバルティス アクチエンゲゼルシャフト Ｃｎｔｆ遺伝子多型に基づく、精神病および統合失調症の処置方法
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
RS20060035A (en) * 2003-07-22 2008-08-07 Arena Pharmaceuticals Inc., Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
ES2825949T3 (es) 2004-09-30 2021-05-17 Vanda Pharmaceuticals Inc Métodos para administrar iloperidona
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
DE102005016981A1 (de) 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
MX2010006521A (es) * 2007-12-13 2010-08-10 Vanda Pharmaceuticals Inc Metodo y composicion para el tratamiento de una condicion mediada por el receptor de serotonina.
US8729100B2 (en) * 2007-12-13 2014-05-20 Vanda Pharmaceuticals, Inc. Method and composition for treating an alpha adrenoceptor-mediated condition

Also Published As

Publication number Publication date
HRP20140701T1 (hr) 2014-11-21
DK2222300T3 (da) 2014-07-21
US9987264B2 (en) 2018-06-05
WO2009076664A1 (en) 2009-06-18
JP2011506482A (ja) 2011-03-03
NZ585923A (en) 2012-09-28
EP2222300B1 (en) 2014-06-11
AU2008334933A1 (en) 2009-06-18
ZA201004213B (en) 2012-11-28
JP2015051991A (ja) 2015-03-19
MX2010006521A (es) 2010-08-10
SI2222300T1 (sl) 2014-11-28
CA2709104A1 (en) 2009-06-18
JP5925862B2 (ja) 2016-05-25
US20140079685A1 (en) 2014-03-20
AU2008334933B2 (en) 2016-01-21
EP2222300A1 (en) 2010-09-01
BRPI0821131A2 (pt) 2017-10-03
US9446038B2 (en) 2016-09-20
PL2222300T3 (pl) 2015-02-27
CA2709104C (en) 2017-06-13
US8618134B2 (en) 2013-12-31
US20110044971A1 (en) 2011-02-24
US20160361303A1 (en) 2016-12-15
CY1115587T1 (el) 2017-01-04
PT2222300E (pt) 2014-07-28

Similar Documents

Publication Publication Date Title
CL2011001060A1 (es) Compuestos derivados de 4-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil]-piridina, 3-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil)-fenilo, 3-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil)-fenilo; procedimiento de preparacion; composicion farmaceutica; utiles para tratar enfermedades cancerosas o tumorales.
JP4725946B2 (ja) ヒストンデアセチラーゼの新規な阻害剤としてのスルホニル誘導体
TWI567067B (zh) ＴｒＫ抑制化合物
AU2003209727B2 (en) Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
CN107108478B (zh) Urat1抑制剂
FR16C0019I2 (fr) Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep
JP2013521286A5 (es)
NO20072986L (no) 3-fenyl-pyrazol derivater som modulatorer til 5-HT2A serotoninreseptor anvendelig for behandling av forstyrrelser relatert dertil
PE20160521A1 (es) Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida
ES2483366T3 (es) Método y composición para el tratamiento de una afección mediada por el receptor de serotonina
OA12788A (en) Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase.
JP2007507551A5 (es)
JP2010265321A5 (es)
AR051945A1 (es) Formas polimorficas de 6-[2-(metilcarbamoil)fenilsulfanil] -3-e-[2-(piridin-2-il) etenil] indazol
CR20150050A (es) Sales y formas solidas de (s)-3-(4-((4-(morfolinometil) bencil) oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona y composiciones que comprenden y métodos para utilizar las mismas
PE20091565A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
TR201805216T4 (en) COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
HRP20120969T1 (hr) Spoj azola
CO6361993A2 (es) Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina
JP2017500321A5 (es)
PE20120356A1 (es) Compuestos para el tratamiento de trastornos metabolicos
JP2011510985A5 (es)
NO20065022L (no) Substituerte 4-alkyl- og 4-alkanoyl-piperidinderivater og deres anvendelse som neurokininantagonister
Jumppanen et al. Synthesis, identification, and structure–activity relationship analysis of GATA4 and NKX2-5 protein–protein interaction modulators
AU2018205275A1 (en) Methods for the treatment of neurological disorders